Keryx Share Price Tumbles Sharply On Phase III Failure Of Perifosine
This article was originally published in The Pink Sheet Daily
Executive Summary
With disappointing data in advanced colorectal cancer, Keryx is expected to abandon development of the Akt pathway inhibitor and focus all efforts on Phase III candidate Zerenex in ESRD.
You may also be interested in...
New CEO Dodd Up For The Task Of Turning Around Aeterna Zentaris
David Dodd assumed the role of chief executive at the Canadian oncology company in April and has clear plans to create a revenue stream that will help finance its portfolio of oncology candidates.
Zerenex To Be Positioned As Cost-Saving, Oral Alternative In ESRD Setting
Keryx plans to file an NDA for phosphate binder Zerenex during the second quarter, with an EU filing to follow by mid-year. In a long-term Phase III study, the candidate met its primary efficacy endpoint as well as several secondary endpoints.
Regeneron/Sanofi’s Long-Term Alliances Begin Bearing Fruit
Regeneron’s five-year-old antibody partnership with Sanofi may be expensive, but it is starting to produce some interesting compounds in mid-to-late-stage clinical trials, with positive data to show.